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Abstract. The present study evaluated the frequency of the
polymorphism of Interleukin-6 (IL6) in women positive for
E6/E7 Human Papillomavirus (HPV) (n=152) and women
negative for HPV (n=238), 390 women in total. Material for
analysis was obtained at the Federal University of São
Paulo. Interleukin-6 polymorphism was detected by
Polymerase Chain Reaction–Restriction Fragment Length
Polymorphism (PCR-RFLP) and analyzed in 3% agarose gel.
Results: No significant associations between the frequency
of the polymorphism of IL6 in patients expressing E6 and E7
with HPV-positive and -negative reactions were found. There
was no statistically significant difference between the case
and control group for genotype distribution (p=0.280).
Conclusion: Genotypic analysis showed a striking similarity
of IL6 polymorphisms in both cases and controls. The allelic
distribution in cases and controls for G and C of IL6 were
very similar (p=0.186), which could point to similar IL6
functionality for both groups.
Cervical cancer is one of principal causes of death in women
worldwide, competing with breast cancer in developing
countries (1). The oncogenic human papillomavirus (HPV)
is the obligatory etiological cause of cervical cancer
development. A number of co-factors were described such as
host immune characteristics, and number of sexual partners
presumably infected, which increase the chances for HPV
infection and viral load. HPV infection affects men and
women, and HPV can be found in the perianal region, anal
canal, scrotum, penis, semen, oral cavity and pharyngeal and
esophageal regions (2, 3). Importantly, persistent high-risk
HPV infection is the major risk factor for neoplastic
progression (4-7).
There are almost 200 types of HPV biologically identified
as oncogenic and non-oncogenic types, with an estimation
that 75% of all humans will be infected during their life-
time, although only a small percentage of these infections
will develop cancer (8).
The long period between HPV, infection and the diagnosis
of invasive carcinoma (approximately 15 years) indicates that
multiple factors and multiple steps may be required for
carcinoma-development (7, 9 and 10). Recently, several
studies indicated that the detection of persistent high-risk
HPV DNA in cervical cytological samples predicts the
presence of precursor lesions of cervical cancer (11).
Carcinogenesis induced by oncogenic HPV depends on
the activity of the viral oncoproteins E6 and E7 in cellular
repository of the cervix, that culminates with the integration
of the HPV genome into human DNA. Briefly, E6 is
responsible for the degradation of p53, and E7 interferes
with the retinoblastoma protein (pRb) function (12). Both
p53 protein and pRb act as tumor growth suppressors;
consequently, it is predictable that cell-cycle regulation is
critically damaged upon infection by HPV, which induces an
altered S phase distribution and consequently provokes errors
in cellular DNA replication. Not surprisingly, the high-grade
lesions have high rates of E6 and E7 transcripts in all layers
of the epithelium, which is associated with genetic
abnormalities and malignant transformation (13).
Co-factors have been identified for the development of
cervical carcinoma, including exogenous influences such as
smoking, use of oral contraceptives, and micro-organisms
such as Chlamydia trachomatis, among others (14-16).
Most of these factors are believed to enhance
carcinogenesis, including high-risk HPV types,
immunosuppression, and host genetic polymorphisms that
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could modulate the effect of HPV behavior. Polymorphism
of interleukin-6 (IL6), a pro-inflammatory cytokine that
acts on different cells and that is released in almost all
cases of acute infection, is supposedly involved in cervical
cancer aggressiveness. IL6 was studied by Woodworth and
Simpson in 1993 (17), who described that the normal
mucosa produces cervical IL6, but the presence of HPV
influences the local immune response. It was also observed
that high levels of IL6 are expressed in invasive cervical
carcinomas, compared to normal cervix (18).
Considering that specific mutations of certain genes can
be associated with the incidence of some types of cancer,
polymorphisms can affect gene expression and play a role
in oncogenesis, according to recent advances in molecular
genetics, which includes genome-wide association studies
(19).
The IL6 gene is located on chromosome 7p21-24 and IL6
polymorphism is located in the promoter region (-174G/C);
this polymorphism has been previously correlated with
increased concentration of IL6 in plasma; however, the
individual genetic variation is believed to be related to the
pathogenicity of cervical cancer (20, 21).
The study herein reported is a case–control evaluation
comparing the frequency of IL6 polymorphism in patients
with E6 and E7 of high-risk HPV-positive versus -negative
women in order to determine if this polymorphism plays a
role in cervical lesions.
Materials and Methods
Study Population. A total of 390 women were evaluated, 152
formed the case group (HPV-positive, E6- and E7-positive) and 238
controls (HPV-negative, negative for E6 and E7). The average age
was 30.2±7.6 years in the control group and 29.9±9.8 years in the
case group (p=0.778). This work was performed with scraped
cervical samples analyzed at the Laboratory of Molecular
Gynecology, Federal University of São Paulo. The local Ethical
Committee approved the project, n˚ 1275/10.
DNA extraction. The extraction of DNA was performed as per the
Kit ilustra™ blood genomic Prep protocol of GE (Firfield,
Connecticut, EUA) for extraction of the material from blood and
epithelial cell scrapes. The purified DNA was stored at −80˚C until
utilization. The amount of DNA in each sample was measured by
spectrophotometry in a NanoDrop® 2000 (Thermo fisher Scientific-
San Jose, California, USA) 
Restriction Fragment Length Polymorphism assay (RFLP). The
polymorphism of IL6 was analyzed by Polymerase Chain Reaction
(PCR). The primer pairs used were: IL6 (174 position of the
promoter region) - sense: 5’- ATG CCA AGT TCT GAG TCA CTA
3’, - antisense: 5’- GGA AAA TCC CAC ATT TGA TA 3’. 
Ten microliters of Master Mix (PCR Master Mix 2x; Promega -
Madison, Wisconsin, USA) were used, with 1 μl of each primer (10
pmol/μl), 100 ng genomic DNA and Nuclease-Free Water,
(Promega) for 25 μl reaction.
For optimization of the tests, a reaction was carried-out with PCR
using a temperature gradient in order to obtain the best conditions
for the annealing temperature of the primers.
The amplification for the detection of IL6 polymorphism was
carried-out with the following cycling conditions: 94˚C for 5 min
for initial denaturation, followed by 94˚C for 30 s, 54˚C for 45 s
and 72˚C for 1 min for 40 cycles for denaturation, annealing and
extension, with final extension of 72˚C for 7 min to finish the
reaction. All material post-PCR were analyzed on an agarose gel
for confirmation and documented for analysis of viability of each
sample. The products of the PCR amplifications were applied to a
2.0% agarose gel (Amersham Pharmacia Biotech - Piscataway, New
Jersey, USA) and stained with ethidium bromide (1 mg/ml - Promega)
and subjected to electrophoresis for 20 min at 110 V in a horizontal
tank containing running buffer of 0.04 M Tris-acetate and 1 mM
EDTA (pH 8). The visualization of the amplicon was carried out on
an ultraviolet transilluminator and documented by the Kodak Digital
Science 1D photo system (Rochester, New York, USA) (Figure 1).
IL6 polymorphism. Viable samples were digested with restriction
enzyme (NlaIII; Thermo Scientific - San Jose, California, USA) for 2 h
at 37˚C in a water bath following the manufacturer’s protocol.
Polymorphism analysis was performed on an agarose gel (3.0%)
staining with ethidium bromide. The human gene for IL6 is located on
chromosome 7p21-24 and its phosphorylated glycoprotein contains 185
amino acids. The target of this study was a polymorphism located in
the promoter (174 G/C). Digestion with the enzyme NlaIII generated a
fragment of 226 bp for the wild-type allele (G) and 117 bp and 109 bp
for the polymorphic allele (C). In heterozygous (G/C) patients
fragments of 226 bp, 117 bp and 109 bp are generated (Figure 2).
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Figure 1. Agarose gel after amplification of the target segment of
interleukin-6 (IL6) in the DNA of certain patients. The 2.0% agarose
gel was stained with ethidium bromide, showing single fragment of 226
bp of the gene. The numbers 160-174 represent a small portion from our
sample group and M represents a molecular weight standard of 100 bp.
Statistical analysis. Analyses were performed using the Statistical
Package for Social Science (v14.0) (IBM softwares, USA). To
compare qualitative variables between case and control groups, i.e.
frequencies and genotypic and allelic proportions, the Chi-square
test was used, when required. Statistical significance was set at 5%.
Results
Our study included 390 women, 152 in the case group (HPV-
positive, E6/E7-positive) and 238 in the control group (HPV-
negative, E6/E7-negative). There was no statistically significant
differences between the groups according to genotype or allele,
as shown in Tables I, II and III.
Discussion 
Genotypic analysis showed a striking similarity of the
distribution of IL6 polymorphisms in both cases and
controls. This is extremely interesting because it calls into
question the actual role of IL6 in carcinogenesis of the
uterine cervix. The allelic distribution in cases and controls
for G and C was very similar, with no significant (p=0.186)
difference, which could indicate that IL6 functionality is
similar for both groups.
It is well-known that IL6 encodes a cytokine that acts in
inflammatory processes and which has an important role in
cervical carcinogenesis. The polymorphisms of IL6 are
associated with variations in immune response that contribute
to an increased risk of cancer (22). Recently, IL6
polymorphism was shown to be a marker for susceptibility to
cervical carcinoma in 1,584 Chinese women with cervical
carcinoma. However, these data need further evaluation
regarding the relationship between polymorphism and HPV-
induced cervical lesions (23). Our study was based on 152
women positive for HPV E6/E7, but with different degrees of
cervical lesion. The lack of significant differences between
the HPV-positive cases and the group of 238 HPV-negative
women shows the variability of polymorphisms to be
discriminatory only if analyzed in large population. 
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Figure 2. Agarose gel after incubation of the DNA fragment (226 bp)
target interleukin-6 (IL6) with endonuclease NLAIII. The 3.0% agarose
gel was stained with ethidium bromide in the study of IL6 (174 G/C)
polymorphism. The numbers 141-159 represent a small portion from our
sample group and M represents a molecular weight standard of 100 bp.
In the columns marked 143, 145, 146, 147, 149, 155, 157 and 158, note
the presence of fragments reflecting the homozygous  wild-type for the
polymorphism (G/G); columns 142 and 159 reveal the mutated
homozygous pattern of  polymorphism (C/C); 141, 144, 148, 154 and
156 have the heterozygous pattern (G/C) for the IL6 polymorphism.
Table I. Distribution of genotypic polymorphism for interleukin-6.
Genotype
Group GG n(%) CG n(%) CC n(%) Total n(%) p-Value*
Case 89 (58.6) 51 (33.6) 12 (7.9) 152 (100) 0.280
Control 158 (66.4) 63 (26.5) 17 (7.1) 238 (100)
*Chi-square test.
Table II. Distribution of cases and controls by interleukin-6 G-carrying
genotype.
Groups
Genotype Case n(%) Control n(%) p-Value*
GG 89 (58.6) 158 (66.4) 0.144
Non-GG 63 (41.4) 80 (33.6)
Total 152 (100) 238 (100)
*Chi-square test.
Table III. Distribution of alleles for interleukin-6 polymorphism.
Group
Allele Case n(%) Control n(%) p-Value*
G 229 (75.3) 379 (79.6) 0.186
C 75 (24.7) 97 (20.4)
Total 304 (100) 476 (100)
*Chi-square test.
The genotype distribution between cases and controls had
homogeneous proportions (p=0.280) for those with wild-type
(GG: 58.6% of cases and 66.4% of controls), heterozygous
(GC: 33.6% of cases and 26.5% of controls) and homozygous
(CC: 7.9% of cases and 7.1% of controls) genotypes. Even
dichotomously separating wild genotype versus heterozygous
or homozygous genotypes, did not show any significant
differences (p=0.144), which reinforces, in part, our
assumption of no significant influence of IL6 polymorphism
in women with positive and negative reactions for HPV E6/E7
but without invasive carcinomas. In 131 women with cervical
intra-epithelial neoplasias 2-3 and 209 controls, Grimm and
co-workers observed that the polymorphism of IL1, IL1A889,
but not IL6, was independently associated with an increased
risk for high-grade intraepithelial lesions (24). Conversely,
Gangwar and colleagues evaluated the association of the
polymorphism of IL6 (174G/C) for predisposition to cervical
carcinoma in 160 cases of women with cervical cancer and
200 controls. They found a significant association between IL6
174CC genotype and increased risk of cervical cancer (odds
ratio=3.16, p=0.014), in addition to the increased risk of
developing carcinoma in women with stage I genotype (CG)
(OR=3.63, p=0.003) (25).
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